SCHEMBL310210

SCHEMBL310210

CCCSc1[c]cccc1

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SOAT1 P35610 1/20 0.36
PTGS2 P35354 1/20 0.35
ALDH1A1 P00352 2/20 0.34
DRD2 P14416 1/20 0.34
HPGD P15428 1/20 0.34
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA13 Q8N1Q1 1/20 0.32
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
APLNR P35414 1/20 0.30
GAA P10253 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310860 0.88 SOAT1 (0.39) SOAT1PTGS2ALDH1A1MAOAMAOB
SCHEMBL310542 0.86 SOAT1 (0.41) SOAT1PTGS2RAB9A
SCHEMBL8930349 0.85 SOAT1 (0.42) SOAT1PTGS2
SCHEMBL15844402 0.85 SOAT1 (0.42) SOAT1PTGS2
SCHEMBL11111116 0.85 SOAT1 (0.42) SOAT1PTGS2
SCHEMBL11483337 0.85 SOAT1 (0.42) SOAT1PTGS2
SCHEMBL8943722 0.85 SOAT1 (0.42) SOAT1PTGS2
SCHEMBL2452782 0.85 SOAT1 (0.42) SOAT1PTGS2
SCHEMBL5495850 0.85 SOAT1 (0.42) SOAT1PTGS2
SCHEMBL192919 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022072-B2 Azolylmethylidenehydrazine derivative and use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2011-09-20 US claimed
US-20110118234-A1 Urea Compounds as Gamma Secretase Modulators AMGEN INC. 2011-05-19 US claimed
EP-2300427-A1 UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2011-03-30 EP claimed
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-07-29 US claimed
EP-2168951-A1 AZOLYLMETHYLENEHYDRAZINE DERIVATIVE AND USE THEREOF KAKEN PHARMACEUTICAL CO., LTD. (JP) 2010-03-31 EP claimed
WO-2009137404-A1 UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS AMGEN INC. (US) 2009-11-12 WO claimed
EP-0533837-A4 INHIBITION OF 5-LIPOXYGENASE AND CYCLOOXYGENASE PATHWAY MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 1994-11-17 EP claimed
EP-0533837-A1 INHIBITION OF 5-LIPOXYGENASE AND CYCLOOXYGENASE PATHWAY MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1993-03-31 EP claimed
WO-1991019497-A1 INHIBITION OF 5-LIPOXYGENASE AND CYCLOOXYGENASE PATHWAY MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1991-12-26 WO claimed
CN-109843853-B Composition and method for manufacturing device using the same 东洋合成工业株式会社 2022-09-20 CN disclosed
US-11142495-B2 Composition and method for manufacturing device using same TOYO GOSEI CO., LTD. (JP) 2021-10-12 US disclosed
US-20200048191-A1 COMPOSITION AND METHOD FOR MANUFACTURING DEVICE USING SAME TOYO GOSEI CO., LTD. (JP) 2020-02-13 US disclosed
WO-2016051181-A1 4H-IMIDAZO[1,5-A]INDOLE DERIVATIVES AND THEIR USE AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TD02) MODULATORS REDX PHARMA PLC (GB) 2016-04-07 WO disclosed
US-9163046-B2 Process for producing substituted metallocene compounds for olefin polymerization EXXONMOBIL CHEMICAL PATENTS INC. (US) 2015-10-20 US disclosed
EP-0048136-B1 PROCESS FOR PREPARING ALPHA-AROMATIC GROUP SUBSTITUTED ALKANOIC ACIDS OR ESTERS THEREOF SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1986-06-11 EP disclosed
EP-0168262-A2 Pyrimidine derivatives, processes for preparation thereof and use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-01-15 EP disclosed
US-4539420-A Optically active 1-aromatic-group-substituted-1-alkanones and methods for their manufacture SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1985-09-03 US disclosed
EP-0151702-A2 Alpha-hydroxyketone acetals SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1985-08-21 EP disclosed
EP-0067698-A2 Optically active 1-aromatic-group-substituted-1-alkanones and methods for their manufacture SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1982-12-22 EP disclosed
EP-0048136-A2 Process for preparing alpha-aromatic group substituted alkanoic acids or esters thereof SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) 1982-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118234-A1 Urea Compounds as Gamma Secretase Modulators BACE1, BACE2, PSEN1 SOAT1 2326/4885PTGS2 2052/4885ALDH1A1 2026/4885
US-20200048191-A1 COMPOSITION AND METHOD FOR MANUFACTURING DEVICE USING SAME LBR, LMTK2, MMS19 SOAT1 2111/4885PTGS2 4414/4885ALDH1A1 4785/4885
US-11142495-B2 Composition and method for manufacturing device using same LBR, LMTK2, MMS19 SOAT1 2111/4885PTGS2 4414/4885ALDH1A1 4785/4885
US-20100190754-A1 AZOLYLMETHYLIDENEHYDRAZINE DERIVATIVE AND USE THEREOF ARSA, AHR, HRH2 SOAT1 3414/4885PTGS2 105/4885ALDH1A1 831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.